Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

CvergenX, Inc. Partners with National Cancer Institute to Predict Radiation Therapy Success

Published: Wednesday, April 10, 2013
Last Updated: Wednesday, April 10, 2013
Bookmark and Share
Molecular signature assay could save costs and needless radiation therapy.

A molecular signature index technology that can lead to better radiation therapy decisions for patients with cancer is being developed into a reliable radiosensitivity test by CvergenX, Inc., an advanced cancer diagnostics company. It is being done in conjunction with the National Cancer Institute’s Clinical Assay Development Program (CADP).

Research collaborations between CvergenX and Moffitt Cancer Center have preliminary data on the molecular signature’s efficacy in trials for patients with rectal, esophageal, head and neck cancers and, most recently, for patients with breast cancer. The NCI has selected the technology, called InterveneXRT ™, for further development and validation in a commercial collaboration agreement with CvergenX with the aim of making an assay that is ready for use in clinical trials and approval by the U.S. Food and Drug Administration.

To date, the technology has been developed and correlated with retrospective clinical outcomes over more than seven years of research and with the help of more than $2 million in funding primarily from the NCI.

“Developing a radiosensitivity predictive assay has been a goal of radiation biology for decades,” said Javier F. Torres-Roca, M.D., a member of the Radiation Oncology, Chemical Biology and Molecular Medicine Programs at Moffitt and co-founder and chief scientific officer of CvergenX. “This effort supports the emphasis on personalized medicine, where the goal is to use molecular signatures to guide therapeutic decisions.”

According to Torres-Roca, approximately 60 percent of all cancer patients receive radiotherapy during their treatment. Until now, no molecular diagnostic or biomarker for radiosensitivity had been developed to predict its benefit. Once the assay is fully developed, Intervene XRT ™ may reduce the need for radiation therapy when the assay shows which patients will or will not respond to treatment.
The radiosensitivity molecular signature was originally developed based on gene expression for 10 specific genes and a linear regression algorithm. It was developed in 48 cancer cell lines using a systems-biology strategy focused on identifying biomarkers for cellular radiosensitivity.

The initial effort is focused on rectal cancer where preoperative radiotherapy is part of the standard of care for patients with stage 2 or 3 disease. However approximately 40 percent of patients do not experience a clinical response to pre-operative treatment. The CADP goal is to show whether this assay will “identify patients who will not benefit from preoperative chemoradiation (with 90 percent negative predictive value), enabling physicians to make informed decisions about the use of chemoradiation for these patients.”

The work will be done by the Clinical Assay Development Network, a nationwide network of CLIA certified labs (labs conforming to the Clinical Laboratory Improvements Amendments, 1988) who have placed a bid with the NCI to carry out the project. The NCI will provide the financing, expertise and labor for the assay development.

According to Mary Del Brady, chairman and CEO of CvergenX, the individualization of radiation therapy is an important component of personalized cancer treatment.

“We are the first commercial enterprise to develop a companion diagnostic to radiation therapy, joining a growing group of personalized medicine companies that are applying genomics-based analysis to clinical practice,” said Brady. “Our goal is to have a validated test with proven clinical utility in the marketplace within the next three years. The test will provide more information, and far greater accuracy, than oncologists have ever had, enabling them to adjust their clinical management for better outcomes for their patients.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!